Product Description: GSK2801 is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4[1].
Applications: Cancer-programmed cell death
Formula: C20H21NO4S
References: [1]Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24./[2]Bevill SM, et al. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer. Mol Cancer Res. 2019 Jul;17(7):1503-1518.
CAS Number: 1619994-68-1
Molecular Weight: 371.45
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Apoptosis;Epigenetic Reader Domain
Deutsch
English
